Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of AK139 injection in patients with inadequately controlled moderate-to-severe asthma
CTR20260341Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK139 in asthma, sponsored by Akeso, Inc.. Started Jun 2026; status: active.
02
Drugs
AK139
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20260341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260341.